numer
modif
wellknown
antimalari
drug
primaquin
quinolin
ring
primari
amino
group
report
mostli
obtain
antimalari
agent
improv
bioavail
reduc
toxic
andor
prolong
activ
modif
termin
amino
group
made
main
idea
prevent
metabol
pathway
lead
inact
toxic
carboxyprimaquin
followon
strategi
also
get
compound
differ
activ
repurpos
strategi
modif
undertaken
includ
review
publish
year
present
review
cover
variou
class
primaquin
nderiv
divers
biolog
profil
prepar
last
decad
research
group
well
other
summar
synthet
procedur
appli
prepar
discuss
main
biolog
result
sever
hit
develop
novel
antiplasmodi
anticanc
antimycobacteri
antibiofilm
agent
identifi
although
develop
firstinclass
drug
novel
mode
action
consid
truli
innov
mani
approach
use
drug
research
develop
like
followon
analoguebas
drug
discoveri
productrel
research
platform
drug
strategi
could
result
lower
cost
lower
risk
failur
shorter
time
market
drug
reposit
repurpos
ie
find
new
indic
existingapprov
drug
increasingli
util
strategi
search
novel
medicin
exampl
antiparasit
antimycobacteri
use
antimalari
drug
repurpos
antimalari
drug
anticanc
agent
particularli
interest
sinc
differ
class
antimalari
display
either
direct
adjuv
activ
cancer
act
sensit
revers
resist
tumour
cell
line
inhibitor
drug
resist
develop
synergist
agent
known
anticanc
drug
hydroxychloroquin
chloroquin
antimalari
agent
artesun
quinacrin
atovaquon
doxycyclin
evalu
current
evalu
numer
clinic
trial
approxim
differ
cancer
type
alon
combin
convent
anticanc
drugstreat
derivat
regist
antimalari
drug
particularli
hybrid
variou
scaffold
also
popular
strategi
search
novel
biolog
activ
agent
divers
biolog
profil
focus
research
antimalari
drug
primaquin
pq
use
start
compound
derivat
pq
drug
develop
market
today
year
still
world
health
organ
list
essenti
medicin
primaquin
activ
gametocyt
exoerythrocyt
form
speci
parasit
caus
human
malaria
includ
chloroquineresist
plasmodium
falciparum
registr
tafenoquin
drug
avail
worldwid
latent
liver
form
relaps
malaria
caus
p
vivax
p
oval
gener
consid
safe
welltoler
drug
howev
appli
primaquin
broad
scale
complic
due
sever
toxic
subset
patient
inherit
dehydrogenas
defici
pitfal
primaquin
quick
metabol
degrad
inact
carboxyprimaquin
alter
treatment
outcom
depend
cyp
enzym
activ
order
get
antimalari
agent
improv
bioavail
reduc
toxic
andor
prolong
activ
modif
primaquin
structur
quinolin
heterocycl
primari
amino
group
perform
main
goal
termin
amino
group
modif
prevent
metabol
pathway
lead
inact
toxic
carboxyprimaquin
modif
undertaken
review
detail
vale
et
al
two
main
set
compound
describ
primaquin
deriv
imidazoquin
amino
acidpeptid
deriv
combin
e
primaquin
peptid
deriv
bear
moieti
compound
evalu
primarili
antimalari
agent
test
anticanc
antifung
activ
howev
present
review
cover
variou
class
primaquin
nderiv
prepar
last
decad
research
group
other
two
goal
get
novel
antiplasmodi
agent
followon
strategi
get
novel
compound
differ
biolog
activ
repurpos
strategi
research
group
prepar
variou
class
primaquin
deriv
amid
carbam
urea
hydroxyurea
acylsemicarbazid
bisurea
ureidoamid
dicarboxyl
acid
deriv
gener
structur
portray
fig
structur
whole
librari
compound
given
si
tabl
pqderiv
prepar
common
synthet
procedur
use
triazol
bth
synthet
auxiliari
versatil
use
bth
synthet
organ
chemistri
well
document
scientif
literatur
research
group
also
huge
experi
benzotriazoleassist
synthes
result
publish
scientif
paper
summar
synthet
procedur
appli
prepar
variou
class
primaquin
deriv
discuss
main
biolog
result
shall
start
review
hybrid
molecul
bear
primaquin
cinnam
acid
ca
motif
cinnam
acid
deriv
cad
natur
occur
substanc
variou
pharmacolog
activ
antimicrobi
antifung
antivir
antimycobacteri
antiinflammatori
antioxid
find
anticanc
antimalari
activ
prompt
us
prepar
pqcad
hybrid
amid
acylsemicarbazid
type
cinnam
acid
follow
cad
use
amethylcinnam
acid
methoxi
dimethoxi
trimethoxi
methylenedioxi
chloro
fluoro
trifluoromethyl
bistrifluoromethyl
cinnam
acid
amid
prepar
simpl
acyl
pq
cad
chlorid
cadcl
cadbenzotriazolid
cadbt
scheme
hand
pqcad
acylsemicarbazid
obtain
acyl
precursor
correspond
cad
chlorid
amid
primaquin
cinnam
acid
alkyl
halogen
nitro
substitu
differ
posit
benzen
moieti
ncinnamoylprimaquin
conjug
primacin
prepar
p
erez
et
al
primaquin
coupl
correspond
cinnam
acid
presenc
tetrafluorobor
tbtu
n
ndiisopropylethylamin
diea
primacin
shown
increas
vitro
activ
liver
stage
rodent
malaria
parasit
p
berghei
compar
parent
drug
primaquin
modest
activ
leishmania
infantum
inact
erythrocyt
stage
p
falciparum
portugues
research
group
report
triplestag
antimalari
ionic
liquid
base
primaquin
cinnam
acid
found
superior
analog
amid
hybrid
order
obtain
potenti
antioxid
andor
anticanc
agent
prepar
amid
conjug
primaquin
nonsteroid
antiinflammatori
drug
nsaid
ibuprofen
ketoprofen
fenoprofen
hydroxi
methylen
ketoprofen
analogu
diclofenac
indomethacin
scheme
deriv
design
bear
mind
sever
fact
inflamm
often
accompani
excess
format
reactiv
oxygen
nitrogen
speci
potenti
damag
dna
cell
membran
ii
oxid
stress
major
contribut
factor
high
mortal
rate
associ
sever
diseas
includ
malaria
cancer
iii
longterm
use
nsaid
associ
lower
risk
cancer
type
iv
nsaid
deriv
pronounc
cytostat
activ
describ
literatur
howev
result
biolog
screen
amid
rather
disappoint
compound
exert
moder
activ
dpph
free
radic
test
bcarotenelinol
acid
assay
neglig
antiprolif
effect
although
ketoprofen
deriv
demonstr
notabl
fe
chelat
abil
acyl
primaquin
acid
chlorid
btccl
gave
deriv
btcpq
common
precursor
synthesi
carbam
urea
respect
scheme
alcoholysi
benzotriazolid
success
methanol
ethanol
fail
alcohol
year
later
sever
oalkyl
oaryl
primaquin
carbam
report
potenti
prodrug
prevent
oxid
deamin
inact
metabolit
carboxyprimaquin
antiplasmodi
screen
reveal
oalkyl
carbam
potenti
develop
transmissionblock
antimalari
agent
aminolysi
benzotriazolid
proceed
mild
condit
especi
presenc
triethylamin
tea
twenti
urea
prepar
includ
twin
deriv
two
pqmoieti
link
carbonyl
group
scheme
bisderiv
previous
prepar
kaur
et
al
reaction
btcpq
obenzylhydroxylamin
gave
compound
afford
nhydroxyurea
catalyt
hydrogen
final
compound
hydrazin
hydrat
gave
pqsemicarbazid
use
intermedi
reaction
step
scheme
anoth
set
urea
deriv
prepar
opposit
way
reaction
primaquin
activ
urea
btcnrr
obtain
btccl
variou
amin
urea
synthes
classic
isocyan
method
eg
directli
pq
fluoromethyl
phenyl
isocyan
synthes
bisurea
deriv
complex
two
synthet
method
bisurea
grow
pq
side
appli
reaction
activ
urea
btcnrr
common
precursor
bisurea
ii
reaction
variou
amin
activ
bisurea
intermedi
obtain
btccl
bisurea
primaquin
use
amin
symmetr
bisurea
bear
two
primaquin
moieti
prepar
invert
reaction
appli
synthesi
bisurea
ie
amin
compon
introduc
first
primaquin
moieti
final
reaction
step
bisurea
obtain
direct
reaction
fluoromethyl
phenyl
isocyan
final
symmetr
bisurea
prepar
reaction
btcpq
ethylenediamin
molar
ratio
scheme
order
obtain
urea
bisurea
deriv
differ
molecular
size
lipophil
flexibl
metabol
stabil
biolog
activ
variou
primari
secondari
amin
use
alkyl
cycloalkyl
amin
amino
alcohol
differ
length
number
hydroxyl
group
rigid
amino
alcohol
bear
small
cycloalkan
moieti
fluorosubstitut
amino
alcohol
amin
one
two
three
benzen
ring
anilin
deriv
halogen
f
cl
cf
mor
pposit
aminophenol
modif
undertaken
follow
common
strategi
drug
design
discoveri
conform
restrict
might
increas
select
enhanc
lipophil
bioavail
presenc
fluorin
atom
might
increas
bioavail
select
dimer
known
antimalari
drug
old
strategi
overcom
drug
resist
improv
antimalari
therapi
outcom
one
symmetr
bisquinolin
deriv
piperaquin
regist
use
malaria
prophylaxi
therapi
twenti
year
today
approv
fixeddos
combin
antimalari
drug
dihydroartemisinin
arterolan
consid
bulki
bisquinolin
compound
accumul
cell
compart
decreas
ph
gradient
inhibit
parasit
hemdigest
pathway
contribut
inhibit
chloroquin
efflux
transport
dimer
strategi
becam
attract
discoveri
effect
anticanc
drug
among
antimalari
well
see
exampl
ref
fact
mind
prepar
three
bispq
deriv
two
primaquin
moieti
connect
linker
bear
one
two
urea
group
quantit
structureact
relationship
qsar
studi
use
support
vector
machin
learn
method
yield
highli
accur
statist
model
use
priorit
novel
scheme
synthesi
primaquin
urea
candid
compound
pqureidoamid
compound
prepar
reaction
pq
nbtcamino
acid
amid
obtain
nbtcamino
acid
chlorid
correspond
amin
hydrazon
scheme
three
amino
acid
lleucin
dphenylglycin
lpchlorophenylglycin
four
amin
pbromoanilin
diphenylmethanamin
phenyl
methanamin
one
hydrazon
hydrazon
use
next
goal
prepar
sahaquin
hybrid
molecul
combin
moieti
suberoylanilid
hydroxam
acid
saha
anticanc
agent
weak
antiplasmodi
activ
primaquin
antimalari
drug
low
antiprolif
activ
fig
compound
design
potenti
histon
deacetylas
hdac
inhibitor
potenti
cytostat
andor
antiplasmodi
agent
sever
panhdac
inhibitor
saha
belinostat
panobinostat
market
anticanc
drug
exert
antiplasmodi
activ
well
hydroxam
group
bind
zinc
ion
zndepend
hdac
lead
accumul
acetyl
histon
protein
addit
three
zndepend
hdac
prone
inhibit
saha
relat
metalchel
drug
identifi
p
falciparum
thu
repres
viabl
target
drug
develop
reaction
pathway
lead
sahaquin
present
scheme
first
reaction
step
dicarboxyl
acid
monoest
coupl
primaquin
give
product
use
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
hatu
coupl
reagent
along
base
diea
basic
hydrolysi
ester
afford
correspond
acid
coupl
obenzylor
omethylhydroxyl
amin
presenc
hatudiea
gave
correspond
oprotect
hydroxam
acid
respect
sahaquin
obtain
catalyt
hydrogen
obenzyl
hydroxam
acid
deriv
succin
fumar
glutar
adip
terephthal
acid
prepar
synthet
procedur
shown
scheme
appli
synthesi
pqhalogenanilin
asymmetr
diamid
fumar
acid
succin
acid
fumardiamid
design
michael
acceptor
analogu
bisurea
succindiamid
satur
counterpart
fumardiamid
miss
bunsatur
carbonyl
group
michael
acceptor
moieti
michel
acceptor
often
use
drug
design
sinc
might
assur
irrevers
coval
bind
cystein
residu
specif
protein
afatinib
neratinib
osimertinib
ibrutinib
exemestan
exampl
regist
anticanc
drug
michael
acceptor
entacapon
dimethyl
fumar
rupintivir
ethacryn
acid
drug
use
therapi
parkinson
diseas
psoriasi
multipl
sclerosi
viral
infect
hypertens
respect
mention
bisurea
fumardiamid
succindiamid
differ
central
part
molecul
nhnh
ch
ch
ch
ch
pqresidu
amin
compon
remain
unchang
structur
formula
bisurea
fumardiamid
succindiamid
compar
fig
primaquin
conjug
glucosamin
two
polym
polyaspartamid
type
poli
b
laspartamid
phea
poli
b
laspartamid
phpa
synthes
scheme
conjug
differ
type
coval
bond
urea
bond
carbam
bond
length
spacer
polymer
carrier
drug
molecular
mass
drugload
main
goal
find
potenti
anticanc
agent
deriv
primaquin
effect
novel
compound
approxim
variou
cancer
cell
line
evalu
second
less
import
goal
find
novel
antiplasmodi
agent
get
complet
biolog
profil
novel
deriv
antimicrobi
antibacteri
antimycobacteri
antifung
antibiofilm
antivir
antioxid
potenti
select
compound
activ
central
nervou
system
cn
evalu
well
gener
bisurea
hydroxam
acid
superior
antiprolif
screen
ureidoamid
fumardiamid
antiplasmodi
antibacteri
evalu
urea
fumardiamid
antimycobacteri
acylsemicarbazid
fumardiamid
antivir
screen
sever
hit
might
present
basi
discoveri
novel
drug
lead
identifi
gain
insight
antiprolif
profil
synthes
primaquin
deriv
evalu
cytostat
activ
vitro
panel
human
cancer
cell
line
si
tabl
result
indic
scaffold
attach
primaquin
signific
impact
activ
select
urea
bisurea
deriv
one
two
trifluoromethyl
group
chloro
methoxybenzhydryl
moieti
trityl
group
sahaquin
hydroxam
acid
scaffold
show
high
activ
test
cell
line
highest
activ
human
breast
adenocarcinoma
cell
line
structur
refer
see
tabl
urea
show
high
select
toward
colorect
adenocarcinoma
wherea
activ
murin
lymphocyt
leukaemia
cell
line
howev
major
scheme
synthesi
dicarboxyl
acid
deriv
compound
display
high
select
toward
cell
eg
symmetr
bispq
deriv
bisurea
hydroxi
halogenphenyl
moieti
observ
surpris
sinc
sensit
cell
line
primaquin
antimalari
drug
document
earlier
bisurea
deriv
pf
poh
substitut
benzen
hydroxypentyl
moieti
twin
primaquin
deriv
promis
compound
antiprolif
screen
due
high
activ
cell
line
extrem
select
favour
druglik
properti
may
consid
lead
compound
discoveri
breast
carcinoma
drug
gener
ureidoamid
variou
dicarboxyl
acid
deriv
inact
wherea
activ
pqcinnam
acid
deriv
compound
hand
sahaquin
contain
free
hydroxam
acid
prove
hdac
inhibitor
antibodi
acetyl
histon
cell
reveal
signific
enhanc
follow
treatment
also
shown
sahaquin
select
inhibit
cytoplasm
nanomolar
concentr
without
markedli
suppress
class
hdac
suppress
epiderm
growth
factor
receptor
downstream
kinas
activ
promin
therapeut
target
glioblastoma
multiform
addit
compound
significantli
reduc
viabil
invas
glioblastoma
tumoroid
well
brain
tumour
stem
cell
crucial
tumour
surviv
recurr
effect
augment
combin
sahaquin
temozolomid
natur
compound
quercetin
buthionin
sulfoximin
inhibitor
glutathion
biosynthesi
antiplasmodi
screen
perform
vitro
vivo
select
compound
five
subset
pq
deriv
amid
urea
moieti
compound
evalu
antiplasmodi
activ
vitro
erythrocyt
stage
p
falciparum
compound
show
weak
activ
ic
mm
compound
strong
activ
low
micromolar
rang
qsar
analysi
obtain
data
yield
highli
accur
statist
model
use
priorit
novel
candid
compound
pqureidoamid
compound
activ
p
falciparum
exhibit
favour
toxic
profil
toward
human
cell
vitro
retain
even
dehydrogenas
inhibit
hand
bisurea
pchlorobenzen
pcf
benzen
dimethoxybenzhydryl
moieti
display
antiplasmodi
activ
vitro
liver
stage
p
berghei
nanomolar
scale
ic
nm
compound
show
antiprolif
activ
low
micromolar
concentr
well
asymmetr
primaquinehalogenanilin
fumardiamid
also
exhibit
high
activ
p
berghei
hepat
stage
higher
parent
drug
ic
valu
rang
mm
ic
primaquin
mm
moder
activ
p
falciparum
erythrocyt
stage
strain
ic
mm
activ
compound
show
low
cytotox
toward
human
cell
also
enzym
inhibit
hand
sahaquin
show
dual
stage
antiplasmodi
activ
correl
cytostat
activ
final
bloodschizontocid
activ
primaquin
conjug
glucosamin
two
polym
polyaspartamid
type
phea
phpa
test
p
berghei
infect
swiss
mice
day
mice
treat
polymer
conjug
either
aparasitem
significantli
p
lower
parasitaemia
compar
negativecontrol
glucosamin
conjug
among
polymer
conjug
compound
appear
best
respect
suppress
parasitaemia
numer
quinolinebear
compound
well
known
antibacteri
drug
mention
import
one
nitroxolin
sever
gener
quinolonefluoroquinolon
deriv
norfloxacin
ciprofloxacin
enoxacin
ofloxacin
moxifloxacin
etc
base
fact
vitro
antimicrobi
activ
select
pq
deriv
urea
bisurea
ureidoamid
pqfumardiamid
succindiamid
carri
panel
gramposit
bacteria
gramneg
bacteria
fungi
list
microorgan
given
supplementari
materi
si
tabl
test
compound
vari
activ
inact
slightli
activ
activ
low
micromolar
concentr
cytotox
well
howev
ureidoamid
show
aureu
show
high
suscept
fumardiamid
e
coli
pneumonia
p
aeruginosa
suscept
five
six
fumardiamid
biofilm
erad
assay
major
bacteria
particularli
aureu
show
suscept
fumardiamid
activ
compound
fluoroderiv
lowest
mbec
mgml
high
biofilm
erad
potenti
fumardiamid
might
explain
reaction
michael
acceptor
cystein
thiol
could
prevent
disulfid
bond
format
wellknown
fact
cystein
homeostasi
impact
biofilm
format
product
extracellular
matrix
compon
well
fold
stabil
extracytoplasm
protein
take
account
fact
quinolin
quinolon
pharmacophor
present
antitubercular
drug
bedaquilin
ciprofloxacin
antimycobacteri
potenti
seventi
primaquin
deriv
evalu
number
mycobacterium
speci
si
tabl
comparison
activ
cytotox
sever
hit
mic
valu
mgml
identifi
mcf
phenylurea
dimethoxybenzhydryl
urea
urea
deriv
methanol
urea
bisurea
phenol
moieti
fumardiamid
pfluorin
chlorin
cf
substitu
biscf
cinnamamid
also
exert
signific
antimycobacteri
activ
mic
mgml
pqurea
deriv
bisurea
deriv
pqcinnam
acid
deriv
pqfumardiamid
pqsuccindiamid
evalu
broad
varieti
virus
si
tabl
urea
phenylethyl
pyridin
moieti
show
specif
activ
human
cytomegaloviru
hcmv
ec
number
studi
shown
prooxid
effect
primaquin
treatment
primaquin
caus
oxid
stress
gener
reactiv
oxygen
speci
within
liver
kidney
erythrocyt
therefor
found
worth
evalu
oxid
antioxid
abil
lipoxygenas
lox
inhibit
primaquin
deriv
amid
urea
type
two
antioxid
assay
use
interact
stabl
free
radic
dpph
test
ii
interact
watersolubl
azo
compound
dihydrochlorid
aaph
inhibit
lipid
peroxid
lp
urea
hydroxyurea
hydroxi
bisurea
semicarbazid
pqcinnam
acid
acylsemicarbazid
almost
bisurea
exert
potent
activ
pqnsaid
show
moder
antioxid
activ
dpph
test
urea
bisurea
lipophil
substitu
show
stronger
lp
inhibit
pqureidoamid
significantli
inhibit
lipid
peroxid
wherea
compound
primaquin
twin
drug
cinnam
deriv
methoxyor
chlorobenzhydryl
substitut
urea
bisurea
present
higher
lox
inhibit
semicarbazideurea
pqderiv
possibl
central
nervou
system
effect
agent
well
select
compound
bear
featur
name
compound
screen
cn
activ
sever
behaviour
test
perform
mice
headtwitch
test
nocicept
reaction
influenc
bodi
temperatur
locomotor
activ
spontan
amphetamineinduc
hyperact
motor
coordin
pentylenetetrazoleinduc
convuls
compound
decreas
bodi
temperatur
normotherm
mice
inhibit
significantli
headtwitch
respons
protect
mice
clonic
seizur
compound
decreas
locomotor
activ
mice
deriv
increas
hyperact
caus
amphetamin
administr
test
compound
show
antinocicept
activ
writh
test
compound
activ
wide
rang
dose
ed
antinocicept
effect
revers
naloxon
tail
immers
test
compound
exert
signific
antinocicept
effect
also
revers
naloxon
none
compound
caus
coordin
impair
rotarod
chimney
test
variou
class
primaquin
deriv
prepar
research
group
gener
structur
present
fig
structur
formula
si
tabl
sinc
compound
prepar
potenti
antiplasmodi
agent
biolog
outcom
present
togeth
chemic
descript
recent
azad
et
al
prepar
nprimaquin
glycosid
overcom
prematur
oxid
deamin
increas
life
span
drug
biolog
system
sugar
part
hybrid
molecul
thought
direct
drug
liver
hypnozoit
resid
titl
conjug
prepar
coupl
primaquin
appropri
monosaccharid
hybrid
molecul
capabl
hit
one
molecular
target
attract
altern
current
approv
antimalari
drug
thu
two
antiplasmodi
drug
differ
mode
action
primaquin
artemisinin
combin
hybrid
amin
amid
coval
bond
primaquin
artemisinin
achiev
accord
procedur
present
scheme
hybrid
prepar
sever
intermedi
artemisinin
dihydroartemisinin
artelin
acid
hydroxam
correspond
aldehyd
reduct
amin
primaquin
afford
titl
hybrid
hybrid
prepar
two
reaction
step
involv
oxid
allyl
correspond
carboxyl
acid
coupl
latter
primaquin
activ
primaquineartemisinin
conjug
liver
blood
stage
plasmodium
compar
vitro
vivo
parent
drug
hybrid
display
enhanc
vitro
activ
p
berghei
liver
stage
similar
activ
artemisinin
p
falciparum
addit
compound
show
signific
vivo
efficaci
control
parasitaemia
small
librari
hybrid
compound
combin
endoperoxid
system
similar
present
artemisinin
primaquin
moieti
prepar
screen
antimalari
activ
scheme
hybrid
show
high
potenc
exoerythrocyt
erythrocyt
form
malaria
parasit
effici
block
develop
sporogon
cycl
mosquito
vector
compound
clear
p
berghei
infect
mice
similar
hybrid
trioxan
motif
synthet
peroxid
caus
damag
parasit
via
product
free
radic
link
chloroquin
relat
aminoquinolin
entiti
easili
penetr
accumul
within
parasit
also
develop
extens
evalu
primaquinechloroquin
conjug
obtain
heat
primaquin
scheme
conjug
consist
primaquin
chloroquin
compon
prepar
valid
concept
util
one
compound
combin
differ
mode
action
attack
differ
plasmodium
stage
inde
conjug
show
activ
plasmodium
liver
blood
stage
high
activ
chloroquin
resist
p
falciparum
strain
superior
equimolar
combin
parent
drug
primaquineferrocen
conjug
primacen
appear
new
class
organometal
compound
synthes
accord
scheme
ferrocen
moieti
introduc
molecul
use
ferrocenecarboxyl
acid
fccooh
bhfc
amino
acid
moieti
standard
method
peptid
chemistri
use
carbodiimid
edc
hydrochloridetea
hexafluorobor
hbtu
diea
coupl
reagent
tertbutoxycarbonyl
boc
nprotect
succinimidyl
su
cactiv
group
primacen
screen
activ
blood
liver
stage
plasmodium
vitro
hostvector
transmiss
vivo
transmissionblock
bloodschizontocid
activ
primaquin
conserv
primacen
bear
basic
aliphat
amin
group
liver
stage
activ
requir
structur
featur
test
metallocen
compar
parent
drug
even
activ
replac
primaquin
aliphat
chain
hexylferrocen
led
activ
liver
stage
parasitaemia
comparison
primaquin
sever
primacen
display
signific
activ
leishmania
infantum
one
activ
clinic
relev
intramacrophag
amastigot
form
parasit
novel
class
hybrid
combin
primaquin
motif
prepar
follow
scheme
threecompon
biginelli
condens
variou
alkylaryl
acetoacet
urea
appropri
aldehyd
gave
one
oxid
one
chlorin
one
condens
primaquin
give
target
compound
effect
pqpyrimidin
hybrid
blood
liver
stage
malaria
parasit
evalu
titl
compound
exhibit
enhanc
liver
stage
antiplasmodi
activ
comparison
primaquin
primaquinethiazolidinon
recent
prepar
multicompon
onepot
reaction
primaquin
mercaptoacet
acid
aromat
aldehyd
bear
halogen
nitro
methoxi
methyl
cyano
substitu
variou
posit
scheme
titl
compound
evalu
sever
biolog
assay
includ
abil
block
malaria
transmiss
mosquito
primaquin
deriv
exhibit
lower
cell
toxic
primaquin
none
caus
haemolysi
normal
human
erythrocyt
vitro
sever
conjug
significantli
inhibit
sporogoni
avian
p
gallinaceum
rodent
malaria
p
berghei
pmethoxi
primaquinethiazolidinon
hybrid
promis
block
malaria
transmiss
reduc
number
exoerythrocyt
form
p
berghei
hepatoma
cell
vitro
mice
vivo
compound
also
caus
delay
malaria
prepat
period
worth
note
introduct
similar
heterocycl
ring
ie
exocycl
c
c
bond
conjug
lacton
c
group
michael
acceptor
primaquin
primari
amin
led
discoveri
antimalari
drug
bulaquin
elubaquin
sinc
bulaquinechloroquin
combin
market
india
treatment
prevent
p
vivax
scheme
synthesi
pqferrocen
conjug
primacen
pqquinoxalin
hybrid
recent
prepar
brasilian
research
group
gener
synthet
approach
synthesi
titl
hybrid
present
scheme
reaction
primaquin
diketen
provid
bacetoacetamid
deriv
react
benzofuroxan
gave
product
compound
identifi
activ
pqbase
hybrid
exoerythrocyt
stage
display
enhanc
liver
activ
p
yoelii
p
berghei
also
inhibit
sporogoni
p
berghei
vivo
liver
efficaci
assay
reveal
compound
show
causal
prophylact
activ
afford
parasitaemia
reduct
day
hand
analog
quinoxalin
hybrid
contain
chloroquin
show
high
activ
erythrocyt
stage
parasit
squaramid
uniqu
scaffold
wide
use
medicin
chemistri
primaquin
monosquaramid
deriv
differ
alkoxi
side
chain
synthes
react
primaquin
wherea
deriv
prepar
reaction
butylamin
prepar
rout
lead
squaramid
given
scheme
compound
potent
liver
stage
parasit
posit
control
primaquin
antiplasmodi
activ
compound
similar
squaramid
squaramid
deriv
two
primaquin
moieti
p
falciparum
strain
also
report
illustr
import
squarat
moieti
activ
atorvastatin
hmg
coa
reductas
inhibitor
use
treatment
hypercholesterolemia
also
exert
antiplasmodi
activ
synergist
effect
dihydroartemisinin
fact
inspir
carvalho
et
al
prepar
pqatorvastatin
hybrid
sever
relat
aminoquinolineatorvastatin
conjug
prepar
achiev
paalknorr
reaction
deriv
correspond
aminoquinolin
synthesi
compound
outlin
scheme
antiplasmodi
activ
vitro
p
falciparum
clone
chloroquin
resist
strain
cytotox
assay
monkey
kidney
cell
line
bgm
show
pqderiv
activ
less
toxic
parent
drug
numer
primaquin
conjug
amino
acid
oligopeptid
pseudopeptid
report
last
decad
primaquin
conjug
amino
acid
contain
free
termin
amino
group
ii
sidechain
amino
group
lysin
ornithin
iii
carboxyl
group
cterminu
iv
sidechain
carboxyl
group
aspart
glutam
acid
standard
synthet
method
common
peptid
synthesi
appli
prepar
use
adequ
protect
group
coupl
reagent
antiplasmodi
screen
reveal
conjug
contain
cation
amino
acid
exhibit
higher
activ
compar
contain
anion
lipophil
acid
exampl
lyslyspq
argargpq
among
activ
peptid
conjug
chloroquinesensit
chloroquineresist
p
falciparum
strain
conjug
produc
suppress
activ
partial
cure
p
berghei
mous
malaria
model
hand
phealapq
show
high
activ
p
vivax
favour
pharmacokinet
profil
compar
parent
drug
valleulyspq
express
reduc
toxic
increas
activ
despit
improv
activitytox
ratio
deriv
rapidli
hydrolys
primaquin
howev
introduct
moieti
protect
ntermin
amino
acid
residu
di
triand
pentapeptid
aminopeptidasecatalys
hydrolysi
bind
primaquin
variou
carrier
lysosomotrop
carrier
gum
arab
microspher
old
idea
gome
collabor
made
approach
interest
recent
report
synthesi
primaquin
conjug
cellpenetr
peptid
transportan
transportan
gener
conjug
activ
liver
stage
p
berghei
parasit
parent
peptid
case
parent
drug
derivat
primaquin
structur
primarili
undertaken
search
novel
antiplasmodi
agent
although
modif
quinolin
part
primaquin
cover
review
want
stress
effort
led
discoveri
novel
antimalari
drug
tafenoquin
hand
modif
primaquin
primari
amino
group
award
registr
bulaquin
elubaquin
howev
increas
resist
current
avail
antimalari
drug
includ
artemisininbas
combin
therapi
urg
need
develop
novel
effici
agent
literatur
survey
reveal
modif
primaquin
molecul
quit
explor
last
decad
success
find
novel
pharmacolog
activ
agent
highli
reactiv
termin
amino
group
allow
modif
variou
deriv
amid
carbam
urea
semicarbazid
ureidoamid
introduct
glycosid
peptid
heterocycl
tetraoxan
pyrimidin
thiazolidon
quinoxalin
squaramid
moieti
hybrid
consist
primaquin
anoth
antiplasmodi
drug
artemisinin
chloroquin
drug
differ
therapeut
group
atorvastatin
result
high
divers
molecul
broad
spectrum
activ
select
achiev
prepar
primaquin
hybrid
display
pronounc
effect
plasmodium
liver
stage
better
activitytox
ratio
parent
drug
hand
hybrid
exert
dual
activ
stage
malaria
parasit
capabl
hit
one
molecular
target
compound
offer
possibl
develop
novel
antiplasmodi
agent
activ
resist
plasmodium
strain
molecular
hybrid
strategi
also
success
search
biolog
activ
agent
outsid
antiplasmodi
field
sever
compound
encourag
antimycobacteri
antibiofilm
activ
identifi
especi
import
find
novel
antiprolif
agent
display
high
potenc
sever
cancer
cell
line
high
select
toward
cell
number
primaquin
deriv
may
consid
lead
compound
discoveri
breast
carcinoma
drug
opinion
research
area
still
exhaust
bright
perspect
lot
work
could
done
futur
studi
support
croatian
scienc
foundat
research
project
work
doctor
student
beu
fulli
support
young
research
career
develop
project
e
train
doctor
student
croatian
scienc
foundat
found
european
union
european
social
fund
